NeurAxis Expands Payer Coverage with Four New Medical Policies
NeurAxis has expanded insurance coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy, with four new medical policies covering approximately 1.25 million lives. The therapy is used to treat functional abdominal pain associated with irritable bowel syndrome and functional dyspepsia.
NeurAxis has announced four new health insurance policies covering its PENFS therapy, representing 1.25 million covered lives. The policies expand access to IB-Stim treatment in West Virginia, New Hampshire, South Carolina, Virginia, and Florida. IB-Stim is a non-invasive neuromodulation device that treats functional abdominal pain associated with irritable bowel syndrome and functional dyspepsia in patients 8 years and older. The therapy is FDA-cleared and addresses a significant unmet medical need, as there are no approved drug therapies for pediatric patients with abdominal pain-related disorders. NeurAxis is a medical technology company focused on neuromodulation therapies for chronic conditions. The company's PENFS technology is being used to treat a large and underserved patient population.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.